within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ06_Semaglutide;
model Semaglutide 
   extends Pharmacolibrary.Drugs.ATC.A.A10BJ06;

  annotation(Documentation(
    info ="<html><body><p>Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus and chronic weight management. It is currently approved for clinical use in both oral and subcutaneous injectable formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy subjects and patients with type 2 diabetes (predominantly adults), after subcutaneous administration.</p><h4>References</h4><ol><li><p>Yang, XD, &amp; Yang, YY (2024). Clinical Pharmacokinetics of Semaglutide: A Systematic Review. <i>Drug design, development and therapy</i> 18 2555–2570. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S470826&quot;>10.2147/DDDT.S470826</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38952487/&quot;>https://pubmed.ncbi.nlm.nih.gov/38952487</a></p></li><li><p>Shi, A, et al., &amp; Haugaard, SP (2021). Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial. <i>Advances in therapy</i> 38(1) 550–561. DOI:<a href=&quot;https://doi.org/10.1007/s12325-020-01548-y&quot;>10.1007/s12325-020-01548-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33159658/&quot;>https://pubmed.ncbi.nlm.nih.gov/33159658</a></p></li><li><p>Hall, S, et al., &amp; Clements, JN (2018). Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. <i>Clinical pharmacokinetics</i> 57(12) 1529–1538. DOI:<a href=&quot;https://doi.org/10.1007/s40262-018-0668-z&quot;>10.1007/s40262-018-0668-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29915923/&quot;>https://pubmed.ncbi.nlm.nih.gov/29915923</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Semaglutide;
